in the myeloablative transplant setting, it is likely to be inadequate for defining GvHD following nonmyeloablative transplantation. Important differences in the temporal peak incidence of organ morbidity, reflective of GvHD symptoms, developing following these two transplant approaches have been recently described, 7 and are highlighted in Table 2 . Following myeloablative allogeneic transplantation, organ morbidity, reflective of GvHD, tends to be bimodal with an early peak in the first 3 months, followed by a smaller late peak at 9-12 months, reflective the classical times of onset (with day 100 cutoff) for development of acute and chronic GvHD, respectively. However, following minimally ablative transplants, manifestations typical of acute GvHD are commonly delayed beyond 100 days, and may often merge with the subsequent onset of more typical manifestations of chronic GvHD. 7 The median time to initiation of corticosteroid therapy, used as an indirect measure of the time to GvHD, was 3.0 months following nonablative transplantation compared to 0.95 months following myeloablative transplants. 7 In this setting, late presentation with erythema and maculopapular rash, nausea, vomiting and diarrhea without detectable oral or ocular sicca or fibrotic manifestations (usually considered typical of chronic GvHD) suggests that alternative criteria are required for acute and chronic GvHD following nonmyeloablative transplants. In agreement with the latter investigators, 7 it will be important to prospectively collect data on qualitative descriptors of GvHD target-organ involvement to permit consensus on criteria defining acute and chronic GvHD in the 'nonmyeloablative' setting, particularly given the marked variability in the intensity of regimens used. With the increased use of nonmyeloablative transplants, this will facilitate the evaluation of different approaches to prevention and treatment of chronic GvHD in clinical trials.
Staging and risk stratification of chronic GvHD
Chronic GvHD is currently staged according to the extent of organ involvement. 16, 17 Patients with localized skin involvement, with or without hepatic dysfunction, are considered to have limited disease. Extensive chronic GvHD is defined as either generalized skin involvement or localized skin involvement in association with eye and/or oral involvement, abnormal liver histology (chronic progressive hepatitis, bridging necrosis, or cirrhosis), or other target organ involvement. Limited disease is associated with a favorable outcome without systemic therapy, while extensive disease patients have an unfavorable outcome. 14, 17 Although this staging system, based on the outcome of only 20 patients, 16 is the main system used today for the classification of patients with chronic GvHD, it has limited utility in defining prognosis and management.
While able to identify patients who require systemic therapy (extensive stage chronic GvHD), the current staging system has significant limitations in predicting prognosis for the majority of patients with chronic GvHD who have higher risk disease, and has been a serious impediment to the development of risk adapted therapy in this condition. Patients with extensive chronic GvHD are quite heterogeneous, and the inclusion of patients of different risk categories that are often poorly defined complicates the interpretation and comparison of reported results. A number of prognostic factors associated with a poor outcome has been reported and are listed in Table 3 . While some of these factors are more reproducible than others, there is no consensus on how the factors interact to stratify patients into different risk categories. Indeed, with the increasing number of agents becoming available for the treatment of chronic GvHD, and therefore, the need to properly evaluate therapy in clinical trials, a consensus on a prognostic system to properly identify patients with different risks is urgently required, as has been achieved in the setting of acute GvHD. Proposed prognostic system for chronic GvHD
Recently, a prognostic model has been proposed. By analyzing clinical data on 151 patients, the relationship between GvHD-specific survival and a number of pretreatment clinical and laboratory variables, including many previously reported to be significant, 14, [19] [20] [21] [22] [23] [24] was investigated. 25 Skin GvHD involving 450% of body surface area, thrombocytopenia (o100 000/ml), and progressive-onset chronic GvHD were identified as independent factors predictive of poor survival (Table 3) . 25 Using the regression coefficients of each of the risk factors, patients could be stratified into four risk groups by a prognostic factor score (PFS). The 10-year chronic GvHD-specific survival for patients with PFS of 0 (no risk factor), less than 2 (skin involvement 450% only or thrombocytopenia and/or progressive-onset type), 2-3.5 (skin involvement 450% and either thrombocytopenia or progressive onset type), and greater than 3.5 (all risk factors) was 82, 68, 34 and 3%, respectively. 25 This system has now been validated in four independent large data sets, including that of patients reported to the International Bone Marrow Transplant Registry. 26 Despite a marked heterogeneity of the patients studied, inclusion of children, variability of GvHD prophylaxis and lack of uniform criteria to evaluate GvHD, the prognostic model successfully separated patients into groups with distinctly different survival. Importantly, the proposed model indicates that extensivestage patients are quite heterogeneous and may, therefore, not all require the same intensity of immunosuppression, particularly given the significant morbidity associated with the latter drugs, 27, 28 and the potential abrogation of any beneficial graft-versus-leukemia effect associated with chronic GvHD. 29, 30 This underscores the need for a riskadapted approach to treatment of chronic GvHD, beyond basing decisions on 'limited-stage' versus 'extensive-stage' disease. The development of uniform definitions and prospective validation of relatively robust prognostic models, such as that proposed by the Akpek et al, 25, 26 will facilitate the design of clinical trials investigating risk adapted therapy.
Primary management of chronic GvHD
As the diverse manifestations of chronic GvHD may mimic a number of other disease processes that can occur in the late post-transplant period, histological confirmation of the diagnosis is critical. 31 The importance of histological confirmation of GvHD in symptomatic organs has been recently emphasized, where up to 27% of patients with suspected chronic GvHD had either no GvHD or inactive chronic GvHD that did not require continuing immunosuppression. 32 Significant morbidity of prolonged immunosuppressive therapy can be avoided in many of these patients.
Patients with 'limited stage' chronic GvHD generally do not require treatment or only topical or local therapy, while patients with 'extensive stage' require systemic treatment. The regimen of alternate-day prednisone and cyclosporine (CsA) has become the standard primary treatment of extensive chronic GvHD. 14, 19, 33 Long-term follow-up of a large randomized study comparing the combination of prednisone and CsA to prednisone alone, however, has shown no additional survival benefit to the use of CsA. 34 The 5-years overall survival was 67% for patients treated with the combination of CsA and prednisone, compared to 72% for patients treated with prednisone only. Importantly, in higher risk patients with 'progressive-onset' chronic GvHD, the addition of CsA did not improve survival, and overall may have worsened it due to increased transplant-related mortality or relapse (Hazard ratio 1.51; 95% CI 1.03-2.21; P ¼ 0.03). CsA, however, reduced steroid-related morbidity, particularly avascular necrosis. 34 The observation that the addition of CsA may have increased transplant-mortality or relapse, however, requires confirmation. While other interpretations are possible, the result may suggest that the low and intermediate risk patients included in the latter study, as defined by the proposed PFS (note all patients had platelet counts 4100 000/ml), 25, 26 may require less immunosuppression given the balance required between GvHD control and adverse effects of therapy. As discussed above, this may further support the need for trials that investigate riskadapted therapy. Alternatively, better immunosuppressive therapies are required for the primary treatment of higher risk patients. Therefore, the investigation of novel agents (see below) in the primary treatment of chronic GvHD is indicated.
'Steroid-refractory' chronic GvHD
Overall, patients who fail to respond to initial corticosteroid-based therapy have a poor outcome, with no standard approach uniformly accepted. Therefore, a large number of agents have been investigated, reflecting the lack of consistently effective treatment in this setting and underscores the need for properly conducted clinical trials. Table 3 Prognostic factors in patients with chronic GvHD
Previously reported prognostic factors
Proposed staging system criteria 25 Extensive stage 14, 16 1. 450% skin involvement Progressive-type onset 14, 19, 20 2. Platelets o100 000/ml Platelet o100 000/ml 14,19À22 3. Progressive-type onset Lichenoid skin histology 20 
Low risk
No risk factor Gastrointestinal involvement 21 Intermediate risk Elevated serum bilirubin 20, 23 450% skin involvement only, OR Age X20 years 21 Platelets o100 000/ml, AND/OR Karnofsky performance status 20, 21 Progressive-type onset Advanced stage malignancy 19 
High risk
No response to therapy at 6 months 21 450% skin involvement, AND Subjective measures of severity 24 Platelets o100 000/ml, OR Progressive-type onset Very high risk: All three risk factors A significant problem is the lack of agreement on the definition of 'steroid-refractory' chronic GvHD. Although progression of GvHD symptoms on corticosteroids has been accepted as fulfilling the definition, lack of response has been less well defined. Indeed, while the lack of response as little as 7 days, or up to 3 months, of corticosteroids has been regarded as sufficient to define refractoriness in some studies, the majority of reports have not specified any duration. In many cases, the treatment is studied after many months or years after failure of primary therapy. It is very likely that this variability in the definition of refractory chronic GvHD is an important confounding factor that could affect the reported efficacy of treatment. Table 4 summarizes the agents reported to be active in 'steroid refractory' chronic GvHD. In many cases the criteria used to assess response are poorly defined, highlighting another difficulty in evaluating efficacy across different studies (see below).
Tacrolimus (FK506)
Although frequently used, tacrolimus appears to have only modest efficacy in the treatment of steroid-refractory chronic GvHD. In a phase II study of 39 patients failing initial treatment with CsA and prednisone, the substitution of tacrolimus for CsA was reported to result in durable remissions in only five patients, with stabilization of the disease in an additional three. 35 These results are similar to previously reported experience, where significant improvement in chronic GvHD occurred in only two of 26 patients. 28 In contrast, a retrospective analysis has emphasized the efficacy of tacrolimus in liver chronic GvHD, where objective responses were observed in nine of 15 patients, five of whom had complete responses. 36 
Mycophenolate mofetil (MMF)
MMF is an ester of mycophenolic acid, which is a reversible inhibitor of inosine monophosphate dehydrogenase, a critical enzyme in the de novo purine synthesis pathway. Since lymphocytes do not possess salvage pathways for purine synthesis, the drug is relatively selective for proliferating B and T cells. MMF may also synergize with tacrolimus. 37, 38 In two retrospective series, responses rates were reported in 69 and 72% of patients refractory to other therapies, including corticosteroids. 39, 40 While gut, oral, liver and nonsclerodermatous skin manifestations were reported to be more responsive to MMF, 40, 41 this was not consistently observed. 39 In both series, however, response criteria were different and poorly defined; in one series response was defined as the ability to reduce or discontinue the dose of MMF or other immunosuppressive drugs. 39 The combination of MMF and tacrolimus resulted in objective responses in 46% of 26 refractory chronic GvHD patients, and is currently undergoing prospective investigation for safety and efficacy. 38 
Thalidomide
Thalidomide has been investigated in a number of retrospective and phase II studies. The drug possesses antiinflammatory and immunomodulatory properties that may underlie its activity in chronic GvHD. 42 However, there is significant variability in the reported response rates across studies. An early study in 42 patients with 'high-risk' and refractory chronic GvHD reported complete and partial responses in 14 and 12 patients, respectively, for an overall response rate of 62%. 43 Although similar response rates have been reported in small series of pediatric and adult patients, 44, 45 responses that are more modest have been reported in larger series. 46, 47 In the largest prospective phase II study, only 16 of 80 patients demonstrated objective responses to therapy. 48 Contrary to other reports, thalidomide was poorly tolerated, with 39% of patients discontinuing treatment because of side effects. 48 Poor tolerability of thalidomide leading to early discontinuation in 92% of patients was also reported in a randomized trial, preventing assessment of its efficacy in initial therapy of chronic GvHD. 49 
Hydroxychloroquine
Hydroxychloroquine is a lysosomotropic 4-aminoquinoline antimalarial drug effective in the treatment of autoimmune disorders. 50 It interferes with antigen processing and presentation through the major histocompatibility complex class II pathway by raising lysosomal pH, 51 and reduces production of proinflammatory cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-a. 52, 53 In addition, it synergizes with CsA and tacrolimus in suppressing T-cell responses to endogenous antigens, including minor and major histocompatibility antigens. 54 In a phase II trial of patients with steroid-refractory and steroid-dependent chronic GvHD, treatment with hydroxychloroquine resulted in three complete and 14 partial responses in 32 evaluable patients after a median of 8 weeks of treatment. 55 Skin, liver and oral mucosa appeared to be the most responsive sites of GvHD. 55 Based on these results, hydroxychloroquine, in combination with CsA and prednisone, is currently being investigated for the primary treatment of extensive chronic GvHD.
Clofazimine
Clofazimine is an antimycobacterial drug with immunomodulatory properties that has also shown activity in a number of immune-mediated skin diseases, including annular lupus erythematosis and pyoderma gangrenosum. 56, 57 A phase II study reported partial responses in eight of 16 patients with extensive chronic GvHD. 58 In particular, over 50% of patients with skin and oral GvHD responded. Remarkably, improvement in joint mobility was observed in six of 11 patients, four of whom attained complete remission of contractures. 58 In spite of recommendations for further investigation of this drug, no other studies have been conducted.
Etretinate
Etretinate is a synthetic vitamin A derivative that is effective in the treatment of scleroderma and the cutaneous manifestations of mycosis fungoides and Sezary Highest responses seen in skin GvHD (67%), although responses also seen in gut (2/3) and oral mucosa (4/13) syndrome. 59 The drug has been reported to be particularly effective in sclerodermatous chronic GvHD, which is generally poorly responsive to therapy. A case series reported significant clinical improvement in sclerodermatous GvHD in 20 of 27 evaluable patients, including softening of skin, flattening of cutaneous lesions, increased range of motion and improved performance status. 60 Although the effect of etretinate on other organs involved by chronic GvHD was not reported, it is likely that the drug will be most effective in combination with other agents with known activity in noncutaneous sites.
Phototherapy and extracorporeal photophoresis (ECP)
Photoinactivation of antigen presenting cells and T lymphocytes is an alternative modality for the treatment of chronic GvHD. Phototherapy of skin lesions of chronic GvHD with either ultraviolet B (UVB) 61 or UVA light following oral administration of psoralen (PUVA) [62] [63] [64] has been shown to be effective in a proportion of patients. In the largest series, 31 of 40 patients with cutaneous chronic GvHD improved with the addition of PUVA to their immunosuppressive regimen, 16 of whom had complete resolution. 64 Anecdotal reports of improvement of oral GvHD with PUVA have also been made. 64, 65 No significant effect is reported in other organs. A more systemic immunomodulatory effect, however, has been achieved with ECP, where direct exposure of peripheral blood mononuclear cells to UVA-activated 8-methoxypsoralen by apheresis is administered. Complete responses of cutaneous chronic GvHD have been reported in up to 80% of steroid-refractory patients, with improvement even in sclerodermatous skin. [66] [67] [68] [69] Improvement in visceral chronic GvHD has been less consistent. Reports of high complete response rates in hepatic 66 and gut GvHD 67 have not been consistently observed. 68 No clinical factor predicting response to ECP has been observed, 67, 68 although in one study, the presence of populations of clonal T cells with unique T-cell receptor gamma gene rearrangements was strongly predictive of response. 70 Importantly, responses to ECP appear to be more frequent in patients treated earlier after diagnosis of chronic GvHD. 68 Furthermore, patients responding to ECP had a significantly longer survival than those who failed to respond. 68 While responses to ECP have been linked with normalization of CD4/CD8 ratios, increase in NK cells, and a decrease in the number of circulating CD80 þ
CD123
þ dendritic cells, 71 this was not observed in a larger series of patients. 68 Other novel agents Several other agents are being investigated in the treatment of chronic GvHD. Pentostatin is a purine nucleoside analogue that irreversibly inhibits adenosine deaminase, with accumulation of dATP, which causes cell death in lymphocytes. Treatment with pentostatin creates a state similar to severe combined immunodeficiency. 72, 73 The effect of pentostatin on T lymphocytes and the importance of these cells in the pathogenesis of GvHD have stimulated investigation of this drug in acute 74 and chronic GvHD. 75 and the monoclonal antibody, infliximab. 76 Other monoclonal antibodies have also demonstrated activity in small case series, including daclizumab 77 and rituximab. 78 Interestingly, responses to rituximab suggest that B-cell dysregulation may also be important in the pathogenesis of chronic GvHD. Larger studies are required to assess the true efficacy of these antibodies in chronic GvHD.
Therapeutic decisions
A large number of options appear to be available for the treatment of chronic GvHD after failure of initial therapy. A major difficulty, however, is the choice of the optimal salvage therapy. In most cases, the choice is at best arbitrary. No results of randomized trials are available to guide therapy. Indeed, the majority studies are small retrospective case series with only a few prospective trials conducted. Furthermore, the marked heterogeneity of patients included in these studies has resulted in a wide range of reported response rates, which inspire either optimism or lack of enthusiasm for a particular therapy depending on personal bias, and makes meaningful comparisons across studies almost impossible. Clearly, there is need for large prospective trials.
Several important variables need to be resolved, however, before meaningful trials can begin (Table 5) . First, as discussed above, there is no agreed definition of 'steroid refractory' chronic GvHD. It is also likely that not all patients with 'steroid-refractory' disease have a uniformly poor outcome. 25 Akpek et al 25 have investigated the outcome of patients with steroid-refractory chronic GvHD. Four factors significantly associated with survival, measured from the time of primary treatment failure, were identified, including 450% skin involvement, thrombocytopenia (platelets o100 000/ml), progressive-onset GvHD and Karnofsky performance status o50%. Patients with none or one risk factor had a relatively good outcome with 5-year GvHD-specific survival of 81%, compared to 25% and 0% for patients with 2-3 and all four risk factors, respectively. 25 While this prognostic system requires prospective validation, the results suggest that imbalance in the distribution of patients across different studies may be a major confounding factor. In addition, there is no consensus on response criteria in chronic GvHD; definitions of response have markedly varied or been poorly defined in different studies. Consensus on these major issues will constitute a major advance toward the design of future trials, and will render meaningful comparisons possible. Finally, the use of more objective end points other than response should be considered, together with impact on quality of life.
Conclusion
Chronic GvHD remains a major obstacle for successful allogeneic stem cell transplantation. With a large number of potential active drugs available for chronic GvHD, however, there is cause for optimism. The major challenge over the next decade will be the design of clinical trials that will give meaningful results. This will involve better risk stratification of patients, as well as better definition of study populations and the end points targeted. Cooperative efforts between investigators will permit a shift toward larger prospective efficacy trials, as well as randomized comparative trials. With the possibility that different drugs may be more effective in certain involved organs, specific combination therapies should also be tested. In addition, as successful initial treatment of chronic GvHD may be the best strategy to improve overall outcome, many of the newer agents should be tested earlier in the disease course. Finally, with a large number of available agents, one option is the design of randomized parallel phase II studies to more rapidly define which agents should be taken to further testing in more definitive phase III trials. Inadequate definition based on time of onset after transplant Late onset of GvHD in nonmyeloablative transplantation 2.
Marked heterogeneity of patients with extensive chronic GvHD No consensus on risk classification 3.
Nonuniform response criteria Responses in some organs are subjective and difficult to assess (eg scleroderma) 4.
No agreed definition of 'refractory' GvHD Refractory patients are heterogeneous 5.
End points other than response are needed Progression-free survival GvHD-specific survival Overall survival Quality of life 6.
Paucity of large prospective trials
